Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
Long COVID-19
Post-COVID-19 Syndrome

Interventions

DRUG: Naltrexone
DIETARY_SUPPLEMENT: NAD+

Sponsor

AgelessRx